Gregory R. Steinberg, PhD, Receives American Diabetes Association’s 2017 Outstanding Scientific Achievement Award


Michelle Kirkwood

Arlington, Virginia
May 8, 2017

Gregory R. Steinberg, PhD, is the recipient of the American Diabetes Association® (Association) 2017 Outstanding Scientific Achievement Award (OSAA). Dr. Steinberg will be recognized with this honor, given annually in recognition of research in diabetes that demonstrates particular independence of thought and originality, at the Association’s 77th Scientific Sessions, June 9-13, 2017, at the San Diego Convention Center. He will deliver the OSAA Lecture, titled “Energy Sensing and Metabolism: Implications for Treating Diabetes,” on Monday, June 12.

Dr. Steinberg is Professor of Medicine, Canada Research Chair and J. Bruce Duncan Endowed Chair in Metabolic Diseases, and Co-Director of the Metabolism and Childhood Obesity Research Program at McMaster University, Ontario, Canada. His research contributions have significantly shaped our understanding of how lipid metabolism, insulin sensitivity and energy sensing are intimately linked and contribute to the development of type 2 diabetes.

“Congratulations, Dr. Steinberg, on this achievement and your outstanding research into metabolism and blood glucose,” said the Association’s President of Medicine and Science Alvin C. Powers, MD. “You have transformed our understanding of diabetes and opened doors to treatments that may one day substantially improve the lives of people with, and at risk for, diabetes.”

Dr. Steinberg identified important connections between inflammation and fat metabolism and how they contribute to insulin resistance. He found that acetylsalicylic acid, the active ingredient in aspirin, may promote health by increasing the activity of a protein kinase that promotes lipid and glucose homeostasis. Furthermore, he identified the molecular mechanisms explaining how the glucose-alanine cycle maintains blood glucose during prolonged fasting and how exercise and metformin lower blood glucose. Dr. Steinberg’s laboratory recently described the first endocrine factor shown to inhibit brown fat activity as well as a key molecule required for maintaining mitochondrial function in this tissue. These pioneering discoveries have important implications for treating metabolic diseases, and Dr. Steinberg is actively involved in translating this body of science to the development of new therapeutics for treating type 2 diabetes and cardiovascular disease.

The American Diabetes Association’s 77th Scientific Sessions, to be held June 9-13, 2017, at the San Diego Convention Center, is the world’s largest scientific meeting focused on diabetes research, prevention and care. During the five-day meeting, health care professionals have exclusive access to more than 2,500 original research presentations, participate in provocative and engaging exchanges with leading diabetes experts, and can earn Continuing Medical Education (CME) or Continuing Education (CE) credits for educational sessions. The program is grouped into eight interest areas: Acute and Chronic Complications; Behavioral Medicine, Clinical Nutrition, Education and Exercise; Clinical Diabetes/Therapeutics; Epidemiology/Genetics; Immunology/Transplantation; Insulin Action/Molecular Metabolism; Integrated Physiology/Obesity; and Islet Biology/Insulin Secretion. Brenda Montgomery, RN, MSHS, CDE, President of Health Care and Education¹, will deliver her address on Saturday, June 10, and Alvin C. Powers, MD, President of Medicine and Science, will present his address on Sunday, June 11. Eight abstracts were selected by the Scientific Sessions Meeting Planning Committee to be presented on Tuesday, June 13, in the President’s Oral Session. These abstracts represent important research being conducted in the field of diabetes today. In total, the 2017 Scientific Sessions includes 378 abstracts in 49 oral sessions; 2,152 poster presentations including 50 moderated poster discussions; and 360 published-only abstracts.

About the American Diabetes Association

Nearly half of American adults have diabetes or prediabetes; more than 30 million adults and children have diabetes; and every 21 seconds, another individual is diagnosed with diabetes in the U.S. Founded in 1940, the American Diabetes Association (ADA) is the nation’s leading voluntary health organization whose mission is to prevent and cure diabetes, and to improve the lives of all people affected by diabetes. The ADA drives discovery by funding research to treat, manage and prevent all types of diabetes, as well as to search for cures; raises voice to the urgency of the diabetes epidemic; and works to safeguard policies and programs that protect people with diabetes. In addition, the ADA supports people living with diabetes, those at risk of developing diabetes, and the health care professionals who serve them through information and programs that can improve health outcomes and quality of life. For more information, please call the ADA at 1-800-DIABETES (1-800-342-2383) or visit Information from both of these sources is available in English and Spanish. Find us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn)

1 Disclosures for Brenda Montgomery. Employer: AstraZeneca Pharmaceuticals. Montgomery's role as President, Health Care & Education of the American Diabetes Association (Association) is a voluntary position to which she was elected by the members of the Association in 2015. She continues to recuse herself from any and all discussions, decisions or votes that have or could be perceived as having a conflict of interest with her employer.